No effective therapy is available for unresectable soft tissue sarcomas (STS). This unmet clinical need has prompted us to test whether chondroitin sulfate proteoglycan 4 (CSPG4)-specific CAR-redirected cytokine-induced killer lymphocytes (CAR.CIK) are effective in eliminating tumor cells derived from multiple STS histotypes in vitro and in immunodeficient mice.
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes
Leuci, ValeriaFirst
;Donini, Chiara;Mesiano, Giulia;Fiorino, Erika;D'Ambrosio, Lorenzo;Merlini, Alessandra;Medico, Enzo;Capellero, Sonia;Giraudo, Lidia;Cattaneo, Giulia;Iaia, Ilenia;Pignochino, Ymera;Vigna, Elisa;Fagioli, Franca;Aglietta, Massimo;Sangiolo, Dario
Last
2020-01-01
Abstract
No effective therapy is available for unresectable soft tissue sarcomas (STS). This unmet clinical need has prompted us to test whether chondroitin sulfate proteoglycan 4 (CSPG4)-specific CAR-redirected cytokine-induced killer lymphocytes (CAR.CIK) are effective in eliminating tumor cells derived from multiple STS histotypes in vitro and in immunodeficient mice.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2020 CSPG4_Leuci.pdf
Open Access dal 09/09/2021
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
3.66 MB
Formato
Adobe PDF
|
3.66 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
